Merck (MRK) Other Working Capital Changes (2009 - 2026)
Merck (MRK) posted quarterly Other Working Capital Changes of $1.6 billion for Q1 2026, down 56.55% YoY from $3.7 billion in Q1 2025, and up 219.48% sequentially from -$1.4 billion in Q4 2025.
Merck (MRK) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Merck has disclosed Other Working Capital Changes across 18 years of filings, most recently posting $1.6 billion for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 56.55% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.2 billion (down 30.81% YoY), while the FY2025 annual figure was $3.3 billion, up 133.55% from the prior year.
- Other Working Capital Changes grew to $1.6 billion in Q1 2026, from -$1.4 billion in the prior quarter.
- Over the last five years, Other Working Capital Changes for MRK reached as high as $3.7 billion in Q1 2025 and fell as low as -$2.6 billion in Q3 2024.
- The 5-year median for Other Working Capital Changes is $1.0 billion (2024), against an average of $595.5 million.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes plunged 1031.43% — and 2025, when it jumped 123.22%.
- A 5-year view of Other Working Capital Changes shows it stood at -$962.0 million in 2022, then soared by 96.36% to -$35.0 million in 2023, then sank by 1031.43% to -$396.0 million in 2024, then tumbled by 240.91% to -$1.4 billion in 2025, then surged by 219.48% to $1.6 billion in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.6 billion, -$1.4 billion, and -$1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Dec 31, 2025 | -1.35 Bn |
| Dec 31, 2025 | -1.35 Bn |
| Dec 31, 2025 | -1.35 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | -396.00 Mn |
| Dec 31, 2024 | -396.00 Mn |
| Dec 31, 2024 | -396.00 Mn |
| Sep 30, 2024 | -2.58 Bn |
| Sep 30, 2024 | -2.58 Bn |